Bioimpact Capital LLC cut its position in ESSA Pharma Inc. (NASDAQ:EPIX – Get Rating) (TSE:EPI) by 2.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 668,688 shares of the company’s stock after selling 14,599 shares during the quarter. ESSA Pharma accounts for about 1.7% of Bioimpact Capital LLC’s holdings, making the stock its 14th biggest holding. Bioimpact Capital LLC owned about 1.52% of ESSA Pharma worth $9,495,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently bought and sold shares of the business. Bank of America Corp DE grew its stake in ESSA Pharma by 18.1% during the fourth quarter. Bank of America Corp DE now owns 8,194 shares of the company’s stock worth $116,000 after purchasing an additional 1,258 shares during the period. Credit Suisse AG grew its stake in ESSA Pharma by 12.2% during the third quarter. Credit Suisse AG now owns 13,713 shares of the company’s stock worth $110,000 after purchasing an additional 1,487 shares during the period. Swiss National Bank grew its stake in ESSA Pharma by 4.2% during the third quarter. Swiss National Bank now owns 49,100 shares of the company’s stock worth $393,000 after purchasing an additional 2,000 shares during the period. Northern Trust Corp grew its stake in ESSA Pharma by 19.1% during the fourth quarter. Northern Trust Corp now owns 25,559 shares of the company’s stock worth $363,000 after purchasing an additional 4,102 shares during the period. Finally, Rock Springs Capital Management LP grew its stake in ESSA Pharma by 1.0% during the third quarter. Rock Springs Capital Management LP now owns 508,044 shares of the company’s stock worth $4,064,000 after purchasing an additional 5,009 shares during the period.
Separately, Piper Sandler decreased their target price on ESSA Pharma from $50.00 to $20.00 in a research note on Thursday, May 12th.
In other ESSA Pharma news, major shareholder Growth N. V. Biotech sold 25,100 shares of the firm’s stock in a transaction that occurred on Wednesday, April 27th. The stock was sold at an average price of $5.85, for a total value of $146,835.00. Following the completion of the sale, the insider now owns 4,990,714 shares of the company’s stock, valued at $29,195,676.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 9.90% of the company’s stock.
About ESSA Pharma (Get Rating)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.
- Get a free copy of the StockNews.com research report on ESSA Pharma (EPIX)
- The Institutions Are Capping Gains In Take-Two Interactive
- Walmart’s “Everyday Low Prices” Gets Burned By Inflation
- VMWare Inc: Strong Revenues and Excellent Potential
- Time to Ride These 3 Mid Cap Momentum Plays
- Beware The Rebound In Home Depot
Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with MarketBeat.com's FREE daily email newsletter.